Advertisement

MPTP Neurotoxicity And The “Biochemical” Blood-Brain Barrier

  • Sami I. Harik
  • Naji J. Riachi
  • Joseph C. LaManna
Chapter
  • 93 Downloads

Abstract

About 25 years ago, major breakthroughs were made in our understanding of the neurochemistry of the basal ganglia and the biochemical pathology of Parkinson’s disease, which eventually led to the successful introduction of levodopa as replacement therapy for this malady. This dramatic success story, especially after the subsequent introduction of peripheral DOPA decarboxylase inhibitors and dopamine receptor agonists as adjuvants, was hailed as one of the best examples of how basic biomedical research can lead to rational therapies for human diseases. Meanwhile, the cause of Parkinson’s disease, i.e. the progressive degeneration of nigrostriatal dopaminergic neurons, remained unknown. Furthermore, replacement therapy, which was once considered revolutionary, was found to be of little help in the treatment of subjects with advanced Parkinsonism and entirely ineffective in arresting the inexorable progression of Parkinson’s disease. Another important fact that emerged in the last decade concerns the lack of evidence that Parkinson’s disease is a genetic disorder, as evidenced by the absence of increased concordance among identical twins. This led to the belief that it may be caused by environmental factors (if it is not nature, it must be nurture).

Keywords

Monoamine Oxidase Clorgy Line Brain Microvessels Monoamine Oxidase Activity Nigrostriatal Dopaminergic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis, G.C., Williams, A.C., Markey, S.P., Ebert, M.H., Caine, E.D., Reichert, C.M., and Kopin, I.J.: Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res. 1, 249–254, 1979.CrossRefGoogle Scholar
  2. 2.
    P. Langston, J.W. Ballard, P. Tetrud, J.W, and Irwin, I.: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980, 1983.PubMedCrossRefGoogle Scholar
  3. 3.
    Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M., and Kopin, I. J.: A primate model of Parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546–4550, 1983.PubMedCrossRefGoogle Scholar
  4. 4.
    Chiba, K., Trevor, A., and Castagnoli, N. Jr.: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574–578, 1984.PubMedCrossRefGoogle Scholar
  5. 5.
    Markey, S.P., Johannessen, J.N., Chiueh, C.C., Burns, R.S. and Herkenham, M.A.: Intraneuronalgeneration of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311:464–466, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    Heikkila, R.E., Manzino, L., Cabbat, ES. and Duvoisin, R.C.: Protection against the dopaminergic neurotoxicity of 1 methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469. 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Langston, J.W., Irwin, I., Langston, E.B., andForno, L.S.: Pargylineprevents MPTP-inducedparkinsonism in primates. Science 225, 1480–1482, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Chiba, K., Pbterson, L.A., Castagnoli, K.P., Trevor. A.J. and Castagnoli, N., Jr.: Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. DrugMetab. Dispos. 13:342–347, 1985.PubMedGoogle Scholar
  9. 9.
    Javitch, J.A., D’Amato, R.J., Strittmatter, S.M., and Snyder, S.H.: Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82:2173–2177, 1985.PubMedCrossRefGoogle Scholar
  10. 10.
    Ricaurte, G.A., Langston. J.W., DeLanney, L.W., Irwin, I., and Brooks. J.D.: Dopamine uptake blockers protect against the dopamine-depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP) in the mouse striatum. Neurosci. Lett. 59:259–264, 1985.PubMedCrossRefGoogle Scholar
  11. 11.
    Nicklas, W.J., Vyas, I., and Heikkila, R.E.: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahyropyridine. Life Sci. 36:2503–2508, 1985.PubMedCrossRefGoogle Scholar
  12. 12.
    Vyas, I., Heikkila, R.E., and Nicklas, W.J.: Studies of the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Inhibition of NAD-linked substrate oxidation by its metabolites 1-methyl-4-phenylpyridinium. J. Neurochem. 46:1501–1507, 1986.PubMedCrossRefGoogle Scholar
  13. 13.
    Hollinden, G.E., Sanchez-Ramos, J.R., Sick, T.J. and Rosenthal, M.: MPP + increases extracellular potassium in rat striatal slices: Preliminary evidence that consequences of MPP + neurotoxicity are spread beyond dopaminergic terminals. Neurosci. Abstr. 13:1502, 1987.Google Scholar
  14. 14.
    D’Amato, R.J., Lipman Z.P, and Snyder, S.H.: Selectivity of the parkinsonian neurotoxin MPTP: Toxic metabolite MPP + binds to neuromelanin. Science 231:987–989, 1986.PubMedCrossRefGoogle Scholar
  15. 15.
    D’Amato, R.J., Alexander, G.M., Schwartzman, R.J., Kitt, C.A., Price, D.L., and Snyder, S.H.: Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327:324–326, 1987.PubMedCrossRefGoogle Scholar
  16. 16.
    Johannessen, J.N., Chiueh, C.C., Burns, R.S. and Markey. S.P.: Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effect. Life Sci. 36:219–224, 1985.PubMedCrossRefGoogle Scholar
  17. 17.
    Elsworth, J.D., Deutch, A. Y., Redmond, D.E. Jr., Sladek, J.R., and Roth, R.H.: Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Life Sci. 40, 193–202, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Kalaria, R.N. and Harik, S.I.: Blood-brain barrier monoamine oxidase: Enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. J. Neurochem. 49:856–864, 1987.PubMedCrossRefGoogle Scholar
  19. Kalaria, R.N., Mitchell, M.J., and Harik, S.I.: Monoamine oxidases of the human brain and liver. Submitted to Brain.Google Scholar
  20. 20.
    Levitt, P., Pintar, J.E., and Breakefield, X.O.: Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. U.S.A. 79:6385–6389, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Westlund, K.N., Denney, R.M., Kochersperger, L.M., Rose, R.M., and Abell, C.W.: Distinct monoamine oxidase A and B populations in primate brain. Science 230:181–183, 1985.PubMedCrossRefGoogle Scholar
  22. 22.
    Zimmer, J. and Geneser, F.A.: Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP. Neurosci. Lett. 78:253–258, 1987.PubMedCrossRefGoogle Scholar
  23. 23.
    Sayre, L.M., Arora, P.K., Iacofano, L.A., and Harik, S.I.: Comparative toxicity of MPTP, MPP+, and 3,3-dimethyl-MPDP + to dopaminergic neurons of the rat substantia nigra. Eur. J. Pharmacol. 124:171–174,1986.PubMedCrossRefGoogle Scholar
  24. 24.
    Harik, S.I., Schmidley, J.W., Iacofano, L.A., Blue, P., Arora, P.K., and Sayre, L.M.: On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: The effects of perinigral effusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. J. Pharmacol. Exp. Ther. 241:669–676. 1987.PubMedGoogle Scholar
  25. 25.
    Lai, F.M. and Spector, S.: Studies on the monoamine oxidase and catechol-O-methyltransferase of the rat cerebral microvessels. Arch. Int. Pharmacodyn. 233:227–234, 1978.PubMedGoogle Scholar
  26. 26.
    Hardebo, J.E., Emson, P.C. Falck, B., Owman, C., and Rosengren, E.: Enzymes related to monoamine transmitter metabolism in brain microvessels. J. Neurochem. 35:1388–1393, 1980.PubMedCrossRefGoogle Scholar
  27. 27.
    Lasbennes, F., Sercombe, R., and Seylaz, J.: Monoamine oxidase activity in brain microvessels determined using natural and artificial substrates: Relevance to the blood-brain barrier. J. Cereb. Blood Flow Metab. 3:521–528, 1983.PubMedCrossRefGoogle Scholar
  28. 28.
    Kalaria, R.J., Mitchell, M.J. and Harik, S.I.: MPTP neurotoxicity: correlation with blood-brain barrier monoamine oxidase activity. Proc. Natl. Acad. Sci. U.S.A. 84:3321–3525, 1987.CrossRefGoogle Scholar
  29. 29.
    Heikkila, R.E., Hess, A., and Duvoisin, R.C.: Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451–1453, 1984.PubMedCrossRefGoogle Scholar
  30. 30.
    Sundstrom, E., Stromberg, I., Tsutsumi, T., Olson, L., and Jonsson, G.: Studies on the effect of l-ethyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405:26–38, 1987.PubMedCrossRefGoogle Scholar
  31. 31.
    Riachi, N.J., Harik, S.I., Kalaria, R.N., and Sayre, L.M.: On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin’s metabolic patterns in brain microvessels and liver. J. Pharmacol. Exp. Ther. 244:443–448, 1988.PubMedGoogle Scholar
  32. 32.
    Fuller, R.W., and Hemrick-Luecke, S.K.: Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mimicked by 1-methyl-4-phenylpyridinium (MPP+) and not blocked by deprenyl. Life Sci. 39:1645–1650, 1986.PubMedCrossRefGoogle Scholar
  33. 33.
    Johannessen, J.N., Adams, J.D., Schuller, H.M., Bacon, J.P. and Markey. S.P.: 1-methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. Life Sci. 38:743–749, 1986.PubMedCrossRefGoogle Scholar
  34. 34.
    Sundstrom, E., Goldstein, M., and Jonsson, G.: Uptake inhibition protects nigrostriatal dopaminergic neurons from neurotoxicity of 1-methyl-4-phenylpyridinium (MPP +) in mice. Eur. J. Pharmacol. 131:289–292,1986.PubMedCrossRefGoogle Scholar
  35. 35.
    Rakic, P.: Limits of neurogenesis in primates. Science 227:1054–1056, 1985.PubMedCrossRefGoogle Scholar
  36. 36.
    LaManna, J.C. and Harik, S.I.: Regional comparisons of brain glucose influx. Brain Res. 326:299–305,1985.PubMedCrossRefGoogle Scholar
  37. 37.
    Bertler, A., Falck, B., Owman, C., and Rosengren, E.: Localization of monoaminergic blood-brain barrier mechanisms. Pharmacol. Rev. 18:369–385, 1966.PubMedGoogle Scholar
  38. Riachi, N.J. and Harik, S.I.: Differences in monoamine oxidase activity at the blood-brain barrier, not in brain, explain best the mouse strain differences in susceptibility to systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Submitted to Life Sci.Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Sami I. Harik
    • 1
  • Naji J. Riachi
    • 1
  • Joseph C. LaManna
    • 1
  1. 1.Department of NeurologyUniversity Hospitals of Cleveland and Case Western Reserve University School of MedicineUSA

Personalised recommendations